June 2013 | Volume 12 | Issue 6 | Features | 718 | Copyright © June 2013
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department
may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In
addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.
New Recommendations for Pediatric Acne
Acne is one of the most common skin conditions in children
and adolescents, and there are increasing amounts of acne
seen in younger age groups. In addition, acne and acne-like
conditions occur at different ages in childhood, including neonates,
infants, and young children, sometimes associated with
significant disease processes.
Although acne is so common, and there has been a great expansion
in treatment options, there have not been standard guidelines
for the management of pediatric acne, and there is tremendous
variation in acne treatment amongst health care professionals.
On May 1st, Pediatrics (the Journal of the American Academy of
Pediatrics) published new evidence-based recommendations for
the diagnosis and treatment of pediatric acne. These recommendations
were developed through the American Acne Rosacea
Society (AARS) and endorsed by the American Academy of Pediatrics.
The recommendations are a result of a two-year effort of
experts in acne, pediatric dermatology, and pediatrics, co-chaired
by Dr. Lawrence Eichenfield, AARS President-Elect and Chief of
Pediatric and Adolescent Dermatology and Professor of Pediatrics
and Medicine (Dermatology) at Rady Children’s Hospital
and University of California, San Diego, and Dr. Diane Thiboutot,
AARS President and Professor of Dermatology at Pennsylvania
State University College of Medicine.
The publication titled "Evidence-Based Recommendations for the
Diagnosis and Treatment of Pediatric Acne" is authored by Drs.
Lawrence Eichenfield, Andrew Krakowski, Caroline Piggott, James
Del Rosso, Hilary Baldwin, Sheila Fallon Friedlander, Moise Levy,
Anne Lucky, Anthony Mancini, Seth Orlow, Albert Yan, Keith Vaux,
Guy Webster, Andrea Zaenglein, and Diane Thiboutot.
Many issues in acne were identified, researched, discussed,
and distilled into recommendations that should help with appropriate
diagnosis and treatment of acne. Acne can have
tremendous negative psychological as well as physical effects.
"And we really have the tools to minimize these problems," said
Dr. Eichenfield, lead author. "I tell my patients that essentially
all acne can be wiped out, but that we work to figure out what
is the least amount of skin care and medicine we need to do it.
These expert guidelines will help to improve knowledge and
management of acne in all age groups."
The article discusses categorization of acne, as well as acne mimickers
in different age groups including neonates, infants, young children, pre-adolescents, and teenagers. Topics discussed include
diet and acne, the effectiveness, safety, and potential side
effects of over the counter products, topical retinoids (vitamin
A-based medicines), antibiotics, hormonal therapies, and isotretinoin
(a systemic retinoid often called "Accutane," the original
trade name). It includes visual and detailed algorithms to care for
mild, moderate or severe disease, essentially flow charts to help
practitioners navigate a person's treatment selections based on
the type and severity of acne.
The full-text article is available online at: http://pediatrics.aappublications.
New Strategy for Combating Infected Wounds
The presentation entitled “Nitrosoglutathione generating nitric
oxide nanoparticles as an improved strategy for combating Pseudomonas aeruginosa infected wounds,” published in the
December 2012 edition of the JDD, received a third-place award
in the Montefiore Medical Center Young Investigator Research
Competition. Presenter Allison Kutner MSIII, research fellow in
the laboratory of Dr. Adam Friedman, stressed the importance
of seeking out innovative approaches to overcome multi-drug
resistant pathogens such as Pseudomonas that can cause complicated
skin and soft tissue infections (SSTIs). “In this study,
we showed that through nanotechnology we could harness the
broad spectrum antibacterial power of nitric oxide (NO) and its
intermediates, in this case, nitrosoglutathione, to treat aggressive
SSTIs,” said Ms. Kutner. “The ability to provide sustained
release nitric oxide as well as nitrosoglutathione through this
nanoparticle platform overcomes many of the limitations witnessed
with other NO releasing drugs, hopefully bringing us
one step closer to translating NO’s potential to the bedside,”
commented Dr. Friedman.
Epionce Announces New Clinically Proven
Epionce has announced the launch of Intense Defense Anti-
Aging + Repair Serum. Intense Defense Anti-Aging + Repair
Serum is a highly advanced anti-aging serum that stimulates
skin rejuvenation using botanical sources of Vitamins A, B, C,
D and E without the irritation caused by many vitamin-based
serums. “Most currently marketed anti-aging serums offer individual
or combinations of vitamins A, B, C, D, and E. However,
all five of these vitamins are used by the skin in order to function
properly, ie healthy metabolism.” said CEO and Founder of
Epionce, Dr. Carl Thornfeldt. “My goal was to create a product